？Es carcinoma lobulillar infiltrante igual a carcinoma ductal infiltrante? Seguimiento a largo plazo

objective: compare infiltrante lobulillar carcinoma and ductal carcinoma in long-term follow up as stage surgical treatment, neoadyuvante, adjuvant therapy. methods: we studied in ceclines database 841 patients; lobulillar represents 7.25 % (61) and 51.24 % ductal (431). the overall follow up was up to twenty two years with an average of five years. results: the overall survival for lobulillar was 68.1 % and for ductal 60.9 % (p=0.772), the survival according to state was: i lobulillar 96.3 % ductal 90.5, ii 94.4 % vs. 88.4 iii 90.5 and 83.2 respectively (p=0.023). estrogen receptors positive expression for lobulillar compared to ductal was 87.7 % vs. 74.7 %, (p=0.031) and its survival 96.9%vs. 94.0%(p=0.033). the breast conservingsurgery for lobulillar compared to ductal was 57.4 % vs. 63.2 % (p=0.949) survival 85.4 % vs. 82.9 % (p=0.001). the survival reported for patients with lobulillar who received neoadyuvante chemotherapy adjuvant chemotherapy radiotherapy and adjuvant hormonotherapy compared to ductal was 93.4 % 91.3 %, 91.5 % 89.7 %, 92.5 % 89.8 % 92.5 % 88.4 %, respectively p<0.05. conclusions: the overall survival is equal, survival favors. the lobulillar have more positive receptors and survival is better. the tendency to conservative treatment in lobulillar is increasingly. given the hormonal profile and survival according to estrogen receptors patients with ilc, are probably good candidates to participate in neoadyuvante hormone therapy protocols. usually the treatment is the same or similar for both groups.